Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Genflow Biosciences Plc ( (GB:GENF) ) has shared an announcement.
Genflow Biosciences Plc announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, a major global investment event in the healthcare sector. This participation is seen as a strategic move to engage with potential partners and investors as Genflow advances its gene-therapy pipeline, particularly focusing on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which could open new opportunities in the longevity space.
More about Genflow Biosciences Plc
Genflow Biosciences Plc, founded in 2020 and headquartered in the UK with R&D facilities in Belgium, is a biotechnology company that develops gene therapies aimed at slowing the aging process. Their lead compound, GF-1002, targets the SIRT6 gene and has shown promising preclinical results. The company is also conducting a clinical trial on aged dogs and exploring the treatment of MASH, a prevalent chronic liver disease.
Average Trading Volume: 5,898,849
Technical Sentiment Signal: Buy
Current Market Cap: £9.87M
See more data about GENF stock on TipRanks’ Stock Analysis page.